Cargando…

Erratum to: A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma

Detalles Bibliográficos
Autores principales:	Addeo, Raffaele, Caraglia, Michele, De Santi, M. Serena, Montella, Liliana, Abbruzzese, Alberto, Parlato, Ciro, Vincenzi, Bruno, Carraturo, Marco, Faiola, Vincenzo, Genovese, Michele, Cennamo, Gregorio, Prete, Salvatore Del
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2010
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462921/ http://dx.doi.org/10.1007/s11060-010-0415-2

Ejemplares similares

A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
por: Addeo, Raffaele, et al.
Publicado: (2010)

Biweekly fotemustine schedule for recurrent glioblastoma in the elderly: activity and toxicity assessment of a multicenter study
por: Addeo, Raffaele, et al.
Publicado: (2019)

Concomitant treatment of brain metastasis with Whole Brain Radiotherapy [WBRT] and Temozolomide [TMZ] is active and improves Quality of Life
por: Addeo, Raffaele, et al.
Publicado: (2007)

Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports
por: Montella, Liliana, et al.
Publicado: (2009)

High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients: A phase I/II trial
por: Marinelli, Alfredo, et al.
Publicado: (2018)

High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study
por: Guida, Michele, et al.
Publicado: (2010)

Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR
por: Caraglia, M, et al.
Publicado: (2011)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells
por: Roos, Wynand P., et al.
Publicado: (2014)

Effects of fotemustine or dacarbasine on a melanoma cell line pretreated with therapeutic proton irradiation
por: Ristić-Fira, Aleksandra M, et al.
Publicado: (2009)

Regulation of Inflammatory and Proliferative Pathways by Fotemustine and Dexamethasone in Endometriosis
por: Genovese, Tiziana, et al.
Publicado: (2021)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experience
por: Gaviani, P., et al.
Publicado: (2013)

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
por: Guida, Michele, et al.
Publicado: (2018)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

On optimal temozolomide scheduling for slowly growing glioblastomas
por: Segura-Collar, Berta, et al.
Publicado: (2022)

Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: Survival across disease and treatment subgroup analysis and review of the literature
por: Prelaj, Arsela, et al.
Publicado: (2019)

Activity and Safety of Bevacizumab Plus Fotemustine for Recurrent Malignant Gliomas
por: Vaccaro, V., et al.
Publicado: (2014)

High Erk-1 activation and Gadd45a expression as prognostic markers in high risk pediatric haemolymphoproliferative diseases
por: D'Angelo, Velia, et al.
Publicado: (2009)

Squamous cell carcinoma of the tongue in a female with advanced breast cancer: A case report of an elderly patient presenting with two types of cancer
por: ADDEO, RAFFAELE, et al.
Publicado: (2014)

Extended-schedule dose-dense temozolomide in refractory gliomas
por: Berrocal, A., et al.
Publicado: (2009)

Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
por: Lee, S. M., et al.
Publicado: (1993)

Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma
por: Santoni, Matteo, et al.
Publicado: (2013)

Fotemustine: A Third-Generation Nitrosourea for the Treatment of Recurrent Malignant Gliomas
por: Beauchesne, Patrick
Publicado: (2012)

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
por: Brandes, Alba A., et al.
Publicado: (2009)

Immune correlates of metastatic melanoma patients treated with ipilimumab in combination with fotemustine in the phase II NIBIT-M1 study
por: Maccalli, Cristina, et al.
Publicado: (2013)

Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2
por: Becker, J C, et al.
Publicado: (2002)

Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas
por: Corazzelli, Gaetano, et al.
Publicado: (2011)

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients: A Monoinstitutional Experience
por: Lombardi, Giuseppe, et al.
Publicado: (2014)

Retrospective Analysis of Bevacizumab in Combination with Fotemustine in Chinese Patients with Recurrent Glioblastoma Multiforme
por: Liu, Zhiguang, et al.
Publicado: (2015)

Phase III randomized study of fotemustine and dacarbazine versus dacarbazine with or without interferon-α in advanced malignant melanoma
por: Daponte, Antonio, et al.
Publicado: (2013)

Pretreatment but not subsequent coincubation with midazolam reduces the cytotoxicity of temozolomide in neuroblastoma cells
por: Braun, Sebastian, et al.
Publicado: (2015)

A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma
por: Correale, P, et al.
Publicado: (2004)

Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation
por: Fabi, Alessandra, et al.
Publicado: (2009)

The Art of Counseling in the Treatment of Head and Neck Cancer: Exploratory Investigation among Perceptions of Health Professionals in Southern Italy
por: Addeo, Raffaele, et al.
Publicado: (2022)

Marked inactivation of O(6)-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
por: Tolcher, A W, et al.
Publicado: (2003)

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide
por: Ramcharan, Roger, et al.
Publicado: (2015)

Formation and loss of O6-methyldeoxyguanosine in human leucocyte DNA following sequential DTIC and fotemustine chemotherapy.
por: Lee, S. M., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_4ihthcup0sn4h1c53ns37olesp